Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Front Immunol. 2022 May 6;13:879516. doi: 10.3389/fimmu.2022.879516. eCollection 2022.
Sjögren Syndrome (SS) seems to be associated with a greater "overall risk" of cardiovascular (CV) and cerebrovascular events. Although not conventionally considered a feature of the disease, CV events represent a major burden in SS patients. CV risk is the consequence of a complex combination of multiple factors, including traditional risk factors and disease-related mechanisms. A complex relationships between disease-related features, endothelial dysfunction and traditional risk factor has been suggested. Several drugs are available for treating the systemic manifestations of SS, however they have shown positive effects on different outcomes of the disease, but until today the data on the role of these drugs on CV events are scarse. Given these data, the aim of this review was to evaluate the risk of CV risk in primary SS and the effect of the drugs on this manifestation.
干燥综合征（SS）似乎与心血管（CV）和脑血管事件的“总体风险”增加有关。尽管 CV 事件通常不被认为是该疾病的特征，但它们是 SS 患者的主要负担。CV 风险是多种因素复杂组合的结果，包括传统危险因素和与疾病相关的机制。已经提出了疾病相关特征、内皮功能障碍和传统危险因素之间的复杂关系。有几种药物可用于治疗 SS 的全身表现，但是它们对疾病的不同结局显示出积极的效果，但直到今天，关于这些药物对 CV 事件作用的数据仍然很少。鉴于这些数据，本综述的目的是评估原发性 SS 中的 CV 风险以及药物对这种表现的影响。
